MicroRNA-1298 (miR-1298)

MicroRNA-1298 (miR-1298) is a small non-coding RNA molecule that functions as a post-transcriptional regulator of gene expression by binding to the 3′-untranslated regions (3′-UTRs) of target mRNAs, leading to mRNA degradation or translation inhibition[3]. It is generally downregulated in multiple cancer types, including non-small cell lung cancer, breast cancer, glioma, cervical cancer, bladder cancer, and gastric cancer[1][2][3][4]. Functional studies consistently show that miR-1298 acts as a tumor suppressor, with overexpression resulting in inhibition of cancer cell proliferation, migration, invasion, and, in some contexts, promotion of apoptosis[1][2][3][4]. In specific cancers, reported direct targets include CXCL11 (breast cancer), Nidogen-1/NID1 (glioma), connexin 43 (bladder cancer), and possibly KRAS (NSCLC)[1][2][3]. Low miR-1298 expression is associated with poor prognosis and increased tumor aggressiveness, suggesting clinical potential as both a prognostic biomarker and a therapeutic target[1][2][3][4]. No drugs are currently known to target miR-1298 directly.

Other names

hsa-miR-1298MIR1298MIRN1298microRNA-1298-5pmicroRNA-1298-3phsa-mir-1298